Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone

Diclofenac is an important analgesic and anti-inflammatory drug, widely used for treatment of postoperative pain, rheumatoid arthritis, and chronic pain associated with cancer. Consequently, diclofenac is often used in combination regimens and undesirable drug-drug interactions may occur. Because many drug-drug interactions may occur at the level of drug transporting proteins, we studied interactions of diclofenac with apical ATP-binding cassette (ABC) multidrug efflux transporters. Using Madin-Darby canine kidney (MDCK)-II cells transfected with human P-glycoprotein (P-gp; MDR1/ABCB1), multidrug resistance protein 2 (MRP2/ABCC2), and breast cancer resistance protein (BCRP/ABCG2) and murine Bcrp1, we found that diclofenac was efficiently transported by murine Bcrp1 and moderately by human BCRP but not by P-gp or MRP2. Furthermore, in Sf9-BCRP membrane vesicles diclofenac inhibited transport of methotrexate in a concentration-dependent manner. We next used MDCK-II-MRP2 cells to study interactions of diclofenac with MRP2-mediated drug transport. Diclofenac stimulated paclitaxel, docetaxel, and saquinavir transport at only 50 μM. We further found that the uricosuric drug benzbromarone stimulated MRP2 at an even lower concentration, having maximal stimulatory activity at only 2 μM. Diclofenac and benzbromarone stimulated MRP2-mediated transport of amphipathic lipophilic drugs at 10- and 250-fold lower concentrations, respectively, than reported for other MRP2 stimulators. Because these concentrations are readily achieved in patients, adverse drug-drug interactions may occur, for example, during cancer therapy, in which drug concentrations are often critical and stimulation of elimination via MRP2 may result in suboptimal chemotherapeutic drug concentrations. Moreover, stimulation of MRP2 activity in tumors may lead to increased efflux of chemotherapeutic drugs and thereby drug resistance.

[1]  J. Schellens,et al.  Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)* , 2003, Journal of Biological Chemistry.

[2]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[3]  F. Russel,et al.  The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. , 2008, Kidney international.

[4]  Jos H Beijnen,et al.  Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs , 2002, AIDS.

[5]  H. Kusuhara,et al.  Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices , 2007, Journal of Pharmacology and Experimental Therapeutics.

[6]  N. Zelcer,et al.  On the putative co‐transport of drugs by multidrug resistance proteins , 2006, FEBS letters.

[7]  P. Borst,et al.  Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.

[8]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N. Davies,et al.  Clinical Pharmacokinetics of Diclofenac , 1997, Clinical pharmacokinetics.

[10]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[11]  J. Beijnen,et al.  MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid , 2005, International journal of cancer.

[12]  B. Sarkadi,et al.  Differential Modulation of the Human Liver Conjugate Transporters MRP2 and MRP3 by Bile Acids and Organic Anions* , 2003, Journal of Biological Chemistry.

[13]  E. van de Steeg,et al.  Species-Dependent Transport and Modulation Properties of Human and Mouse Multidrug Resistance Protein 2 (MRP2/Mrp2, ABCC2/Abcc2) , 2008, Drug Metabolism and Disposition.

[14]  P. Kogner,et al.  NSAIDs in neuroblastoma therapy. , 2005, Cancer letters.

[15]  Vincent Grégoire,et al.  Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. , 2005, Cancer research.

[16]  F. Russel,et al.  Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport , 2007, Journal of Pharmacology and Experimental Therapeutics.

[17]  X. Chu,et al.  Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  O. Hansson,et al.  PYRIDOXINE AND SERUM CONCENTRATION OF PHENYTOIN AND PHENOBARBITONE , 1976, The Lancet.

[19]  M. Kool,et al.  Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport , 2000, British Journal of Cancer.

[20]  Wei Li,et al.  Human Multidrug Resistance Protein 2 Transports the Therapeutic Bile Salt Tauroursodeoxycholate , 2007, Journal of Pharmacology and Experimental Therapeutics.

[21]  A. Pardee.  Role Reversal for Anticancer Agents , 2002, Cancer biology & therapy.

[22]  Alfred H. Schinkel,et al.  Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.

[23]  H. Rosing,et al.  Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics , 2006, Clinical Cancer Research.

[24]  M. Namer,et al.  CLINICAL AND PHARMACOKINETIC EVIDENCE OF A LIFE-THREATENING INTERACTION BETWEEN METHOTREXATE AND KETOPROFEN , 1986, The Lancet.

[25]  B. Hirst,et al.  Differential Multidrug Resistance-Associated Protein 1 through 6 Isoform Expression and Function in Human Intestinal Epithelial Caco-2 Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[26]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[27]  Wei Li,et al.  ESTRADIOL 3-GLUCURONIDE IS TRANSPORTED BY THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 BUT DOES NOT ACTIVATE THE ALLOSTERIC SITE BOUND BY ESTRADIOL 17-GLUCURONIDE , 2004, Drug Metabolism and Disposition.

[28]  L. Doyle,et al.  Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. , 2000, Cancer research.

[29]  R. Evers,et al.  Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. , 2000, Molecular pharmacology.

[30]  Jos H. Beijnen,et al.  The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models , 2007, Molecular Pharmacology.

[31]  G. Peters,et al.  Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. , 1999, Cancer research.

[32]  J. Beijnen,et al.  Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides , 2007, Molecular Pharmacology.

[33]  J. Lankelma,et al.  Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export , 2000, British Journal of Cancer.